Scientific and Regulatory Policy Committee Points to Consider: Biological Sample Retention From Nonclinical Toxicity Studies. (February 2022)

• Record Type: Journal Article
• Authors: Harbison, Carole E.; Aulbach, Adam D.; Bennet, Bindu M.; Boyle, Molly H.; Carsillo, Mary E.; Crabbs, Torrie A.; Keirstead, Natalie D.; La Perle, Krista M. D.; Pandiri, Arun R.; Shoieb, Ahmed M.; Siska, William D.
• Is Part Of: Toxicologic pathology. Volume 50:Number 2(2022)
• Page Start: 252
• Page End: 265
• Publication Date: 2022-02
• Subjects: Good Laboratory Practice -- toxicologic pathology -- formalin fixed paraffin-embedded -- sample retention -- sample stability -- clinical pathology -- body fluid; Pathology -- Periodicals; Toxicology -- Periodicals; Pathology; Toxicology; 615.9
• DOI: 10.1177/01926233211049156
• Languages: English
• ISSNs: 0192-6233

Abstract

Samples of biologic specimens and their derivatives (eg, wet tissues, paraffin-embedded tissue blocks, histology slides, frozen tissues, whole blood, serum/plasma, and urine) are routinely collected during the course of nonclinical toxicity studies. Good Laboratory Practice regulations and/or guidance specify minimum requirements for specimen retention duration, with the caveat that retention of biologic specimens need not extend beyond the duration of sample stability. However, limited availability of published data regarding stability for various purposes following storage of each specimen type has resulted in confusion, uncertainty, and inconsistency as to the appropriate duration for storage of these specimens. To address these issues, a working group of the Society of Toxicologic Pathology Scientific and Regulatory Policy Committee was formed to review published information, regulations, and guidance pertinent to this topic and to summarize the current practices and rationales for retention duration through a survey-based approach. Information regarding experiences reaccessing biologic specimens and performing sample stability investigations was also collected. Based on this combined information, the working group developed several points to consider that may be referenced when developing or revising sample retention practices. This Points to Consider article is a product of a Society of Toxicologic Pathology (STP) Working Group commissioned by the Scientific and Regulatory Policy Committee (SRPC) of the STP. It has been reviewed and approved by the SRPC and Executive Committee of the STP, the British Society of Toxicologic Pathologists (BSTP) and European Society of Toxicologic Pathology (ESTP) but it does not represent a formal Best Practice recommendation; rather, it is intended to provide key "points to consider" in designing nonclinical studies or interpreting data from toxicity and safety studies in support of regulatory submissions. The points expressed in this document are those of the authors and do not reflect views or policies of the employing institutions. Readers of Toxicologic Pathology are encouraged to send their thoughts on these articles or ideas for new topics to the Editor.